Biodiscovery
A partnership between the National Horizons Centre (NHC) and Canadian start-up Sarissa Inc. focuses on testing the efficacy of a novel therapeutic compound targeting cancers resistant to standard chemotherapy. The project seeks to develop a new treatment approach using RAD51 inhibitors.
One of the biggest challenges in cancer treatment is overcoming resistance to standard chemotherapy, which leaves many cancer patients with limited options. This project aims to evaluate the effectiveness of RAD51 inhibitors, which target DNA repair mechanisms, offering potential treatment alternatives for chemotherapy-resistant cancers.
The NHC is providing cutting-edge research facilities and expertise in pre-clinical cancer models. Researchers are characterising the mechanism of action of RAD51 inhibitors to determine their potential as cancer treatments. The project leverages advanced methodologies in functional characterisation and drug testing to move these compounds closer to clinical trials.
This collaborative effort could lead to significant clinical breakthroughs, offering a new targeted therapy for patients whose cancers do not respond to current treatments. By advancing the understanding of RAD51 inhibitors, the research is poised to bring safer, more effective treatment options to market. The findings will enhance global cancer research and treatment efforts.
